Exploring New Treatment Options for Pediatric Patients with Hodgkin Lymphoma
Rutgers Cancer InstituteWhile gemcitabine and brentuximab vedotin each have benefit when given individually in the treatment of Hodgkin lymphoma, Investigators from the Children’s Oncology Group including a Rutgers Cancer Institute of New Jersey physician-scientist examined the two therapies when combined in pediatric patients. They found the combination to be safe and to have a greater complete response rate than when the drugs are given individually.